Literature DB >> 27021209

Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.

Wen-Qi Hui1, Qi Cheng1, Tian-Yu Liu2, Qin Ouyang3.   

Abstract

Galanin receptor type 2 (GALR2) is a class A G-protein-coupled receptor (GPCR), and it has been reported that orthosteric ligands and positive allosteric modulators (PAMs) of GALR2 could potentially be used to treat epilepsy. So far, the X-ray structure of this receptor has not been resolved, and knowledge of the 3D structure of GALR2 may prove informative in attempts to design novel ligands and to explore the mechanism for the allosteric modulation of this receptor. In this study, homology modeling was used to obtain several GALR2 models using known templates. ProSA-web Z-scores and Ramachandran plots as well as pre-screening against a test dataset of known compounds were all utilized to select the best model of GALR2. Molecular dockings of galanin (a peptide) and a nonpeptide ligand were carried out to choose the (GALR2 model)-galanin complex that showed the closest agreement with the corresponding experimental data. Finally, a 50-ns MD simulation was performed to study the interactions between the GALR2 model and the synthetic and endogenous ligands. The results from docking and MD simulation showed that, besides the reported residues, Tyr160(4.60), Ile105(3.32), Ala274(7.35), and Tyr163(ECL2) also appear to play important roles in the binding of galanin. The potential allosteric binding pockets in the GALR2 model were then investigated via MD simulation. The results indicated that the mechanism for the allosteric modulation caused by PAMs is the binding of the PAM at pocket III, which is formed by galanin, ECL2, TM2, TM3, and ECL1; this results in the disruption of the Na(+)-binding site and/or the Na(+) ion pathway, leading to GALR2 agonism.

Entities:  

Keywords:  Docking; Galanin receptor type 2; Homology modeling; Molecular dynamic simulation; Positive allosteric modulator

Mesh:

Substances:

Year:  2016        PMID: 27021209     DOI: 10.1007/s00894-016-2944-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  59 in total

Review 1.  G-protein-coupled receptor oligomerization and its potential for drug discovery.

Authors:  Susan R George; Brian F O'Dowd; Samuel P Lee
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

2.  A 1H NMR study of the solution conformation of the neuropeptide galanin.

Authors:  A B Wennerberg; R M Cooke; M Carlquist; R Rigler; I D Campbell
Journal:  Biochem Biophys Res Commun       Date:  1990-02-14       Impact factor: 3.575

Review 3.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 4.  The GPCR crystallography boom: providing an invaluable source of structural information and expanding the scope of homology modeling.

Authors:  Stefano Costanzi; Keyun Wang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.

Authors:  L O Gerlach; R T Skerlj; G J Bridger; T W Schwartz
Journal:  J Biol Chem       Date:  2001-01-11       Impact factor: 5.157

6.  Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator.

Authors:  Huixian Wu; Chong Wang; Karen J Gregory; Gye Won Han; Hyekyung P Cho; Yan Xia; Colleen M Niswender; Vsevolod Katritch; Jens Meiler; Vadim Cherezov; P Jeffrey Conn; Raymond C Stevens
Journal:  Science       Date:  2014-03-06       Impact factor: 47.728

7.  Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes.

Authors:  S Wang; T Hashemi; S Fried; A L Clemmons; B E Hawes
Journal:  Biochemistry       Date:  1998-05-12       Impact factor: 3.162

8.  Systemic galnon, a low-molecular weight galanin receptor agonist, reduces heat hyperalgesia in rats with nerve injury.

Authors:  Wei-Ping Wu; Jing-Xia Hao; Linda Lundström; Zsuzsanna Wiesenfeld-Hallin; Ulo Langel; Tamas Bartfai; Xiao-Jun Xu
Journal:  Eur J Pharmacol       Date:  2003-12-15       Impact factor: 4.432

9.  Galnon, a galanin receptor agonist, improves intrinsic cortical bone tissue properties but exacerbates bone loss in an ovariectomised rat model.

Authors:  H W McGowan; J A Schuijers; B L Grills; S J McDonald; A C McDonald
Journal:  J Musculoskelet Neuronal Interact       Date:  2014-06       Impact factor: 2.041

10.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

View more
  4 in total

Review 1.  Allostery at opioid receptors: modulation with small molecule ligands.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

2.  Uncovering new disease indications for G-protein coupled receptors and their endogenous ligands.

Authors:  Johannes M Freudenberg; Ian Dunham; Philippe Sanseau; Deepak K Rajpal
Journal:  BMC Bioinformatics       Date:  2018-10-01       Impact factor: 3.169

3.  In vitro and in silico studies on clinically important enzymes inhibitory activities of flavonoids isolated from Euphorbia pulcherrima.

Authors:  Abdur Rauf; Muslim Raza; Muhammad Humayun Khan; Hassan A Hemeg; Yahya S Al-Awthan; Omar Bahattab; Sami Bawazeer; Saima Naz; Faika Basoglu; Muhammad Saleem; Majid Khan; Hosseini Seyyedamirhossein; Mohammad S Mubarak; Ilkay Erdogan Orhan
Journal:  Ann Med       Date:  2022-01-27       Impact factor: 4.709

4.  Mouse Spexin: (I) NMR Solution Structure, Docking Models for Receptor Binding, and Histological Expression at Tissue Level.

Authors:  Matthew K H Wong; Mulan He; Kong Hung Sze; Tao Huang; Wendy K W Ko; Zhao-Xiang Bian; Anderson O L Wong
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-02       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.